Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.

A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma

Clinical Trial Details

The usual approach for patients, with MCL ≤ 70 years of age, who are not in a study is treatment with a combination of FDA approved drugs including chemotherapy regimens that contain high dose cytarabine and rituximab (an immune therapy). There is not one standard treatment approach that is proven to help patients, with MCL ≤ 70 years of age live longer. Younger people with MCL often undergo autologous stem cell transplantation.

If you decide to take part in this study, you will receive one of the following drug combinations for six cycles with a cycle length of 28 days for a total of 6 months of treatment or until your disease gets worse or the side effects become too severe:

  • Bendamustine, rituximab and high dose cytarabine;
  • Bendamustine, rituximab, high dose cytarabine and acalabrutinib;
  • Bendamustine, rituximab and acalabrutinib

After you finish your study treatment, your doctor will continue to follow your condition for 10 years and watch you for side effects. You will see your doctor every 3 months for 3 years, and then every 6 months until the end of the 10 year period. You should discuss with your doctor how to treat your MCL after you complete this protocol.

Key Eligibility: 
  • Open to men and women between the ages of 18 and 70 with untreated mantle cell lymphoma
  • Detailed eligibility will be reviewed when you contact the study team

Study contact by location

Upper East Side - Manhattan


Amelyn Rodriguez, RN
(212) 746-1362

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:






Open to Enrollment

Age Group